The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on Phase III products like HS-20093, ...

The SMAB will assist the Company in engaging with the US Food & Drug Administration (FDA) regarding the safety and efficacy of its lead immunotherapy product candidate, OST-HER2, for the treatment of ...

Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 ...

Primary bone tumors, such as osteosarcoma, have seen stagnant survival rates over the past four decades. Surgical removal of the tumor is critical, but local recurrence may occur when tumours are ...

A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN)—or, what percentage of a tumor is "dead" and no longer active—in patients ...

Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint ...